COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy.
COVID-19
antiviral
immuno-enhancer
natural products
vaccine
vitamins
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
05
2020
accepted:
17
06
2020
pubmed:
15
7
2020
medline:
22
12
2020
entrez:
15
7
2020
Statut:
ppublish
Résumé
The latest SARS COV2 coronavirus contributes to a pandemic of millions of COVID-19. As there is no defensive immunity in humans and a virus can overcome inborn immune reaction, it can propagate unhindered, mostly in tissues contaminated. No unique therapies for COVID-19 contaminated patients are available at this time. The insights learned from previous respiratory viral infection control have given guidance into COVID- 19 therapy. Several complementary treatments have been tentatively introduced in hospital environments such as immune-modulators, antiviral, convalescent plasma transfusions and natural products. In COVID-19 patients, some of these therapies have provided substantial curative benefits. Moreover, numerous studies and clinical trials are being carried out in order to determine the efficacy of current pharmaceutical and natural products to establish possible therapeutic strategies for producing novel COVID-19 medicines. We summarized and defined the modes of mechanism, protection and efficacy on the existing therapeutic strategies for diseases linked to COVID-19 infection.
Identifiants
pubmed: 32660401
pii: CPD-EPUB-108133
doi: 10.2174/1381612826666200713174140
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5224-5240Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.